Belvarafenib
- Generic Name
- Belvarafenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H16ClFN6OS
- CAS Number
- 1446113-23-0
- Unique Ingredient Identifier
- 31M3WLJ3KG
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04835805
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Germany
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath